Compare Abeona Therapeutics Inc (ABEO) vs Schlumberger NV (SLB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Schlumberger NV — how do they compare? Abeona Therapeutics Inc trades at $6.78 (market cap $373.32M), while Schlumberger NV trades at $46.97 (market cap $69.40B). The key difference: Schlumberger NV is far larger — about 185.9× Abeona Therapeutics Inc's market cap, and Schlumberger NV pays a 2.54% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | SLB | |
|---|---|---|
Market Cap | $373.32M | $69.40B |
Sector | Health | Energy |
52-Week High | $7.23 | $58.01 |
52-Week Low | $4.17 | $31.72 |
Enterprise Value | $228.22M | $77.62B |
Dividend Yield | — | 2.54% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
SLB trades at $46.42, up 2.86% today, amid a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $0.52, exceeding the $0.508 estimate, and holds a strong analyst consensus with a $63.00 price target. Recent news highlights a seven-year digital innovation contract in Kuwait, expanding its energy technology footprint. Cash flow from operations remains robust at $6.49B for 2025, though net cash flow was negative due to significant financing activities.
The outlook is cautiously optimistic, supported by solid fundamentals and growth initiatives in digital and AI, but faces headwinds from oil price volatility and a recent decline in net income margin to 9.26%. The stock presents a potential opportunity given its valuation discounts to analyst targets, though macroeconomic risks and sector cyclicality warrant attention.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Schlumberger NV
Schlumberger is the largest oilfield service firm in the world, with expertise in myriad disciplines, including reservoir performance, well construction, production enhancement, and more recently, digital solutions. It maintains a reputation as one of the industry's leading innovators, which has earned it dominant share in numerous end markets.
Read more on SLB →
